Form 4: Chimerix Director Lisa Decker Disposes of Stock Options in Merger with Jazz Pharmaceuticals

Lisa Decker, a director at Chimerix, disposed of employee stock options as part of the merger agreement with Jazz Pharmaceuticals, receiving cash payment for 'in the money' options.

Summary

• On April 21, 2025, Chimerix merged with a subsidiary of Jazz Pharmaceuticals, following a tender offer for all outstanding shares.
• As a result of the merger, Lisa Decker, a director at Chimerix, disposed of her employee stock options.
• The merger agreement stipulated that 'in the money' options (options with an exercise price lower than the offer price of $8.55 per share) would be accelerated, fully vested, and then cancelled.
• Decker received a cash payment for these cancelled options, calculated as the difference between the offer price and the exercise price, multiplied by the number of shares subject to the option.
• The merger was completed after the filing of the certificate of merger with the Secretary of State of Delaware.

Sentiment

Score: 7

Explanation: The document describes a completed merger, which is generally a positive event for shareholders who receive a cash payment. The sentiment is neutral to positive as it represents the conclusion of a deal.

Positives

• The merger provided a cash payment to option holders like Lisa Decker for their 'in the money' options.

Negatives

• Lisa Decker's stock options were disposed of as part of the merger, meaning she no longer holds those options.

Future Outlook

The document describes the completion of a merger, so there are no forward-looking statements about Chimerix as an independent entity.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

The acquisition of Chimerix by Jazz Pharmaceuticals reflects a trend of consolidation in the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with companies like Pfizer, Novartis, and Roche frequently acquiring smaller biotech firms.
• The $8.55 per share offer price is within the typical range for acquisitions of biotech companies with approved products or late-stage clinical assets.
• Comparable transactions include Gilead's acquisition of Kite Pharma and Takeda's acquisition of Ariad Pharmaceuticals.

Stakeholder Impact

• Shareholders received $8.55 per share in cash.
• Option holders with 'in the money' options received a cash payment.

Key Dates

Keywords

Merger, Chimerix, Jazz Pharmaceuticals, Stock Options, Form 4, Lisa Decker, Acquisition